Sign in
Taking people in United StatesPhase 3

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)

Key facts

Who runs it
Biogen
Where
Cleveland, Dallas, Detroit, Fresno, Greenville, Huntsville, Knoxville, League City, Los Angeles, Madison, Nashville, Pontiac, San Francisco, Stanford, and The Bronx, United StatesSee the 16 sitesAlso in 10 other countries, 101 sites
Status
Recruiting
Phase
Phase 3
People taking part
180 people, planned
Started
22 May 2025
Expected to end
17 Jan 2031
Type of study
Interventional, 2 groups
Treatments tested
  • Felzartamab
  • Tacrolimus
  • Standard of Care IST
Record updated
9 November 2026

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Diagnosed with PMN in need of IST according to the Investigator's clinical judgment. The diagnosis of PMN must be documented with the presence of nephrotic syndrome, and hypoalbuminemia, and confirmed with a kidney biopsy either during Screening or within 5 years of signing the informed consent form (ICF) [see kidney biopsy exception below for participants positive for anti-PLA2R antibodies]. For these participants, the biopsy report with redacted protected health information must be available to be reviewed by the Sponsor or an independent nephropathologist. If the participant requires a kidney biopsy during Screening, medical monitor approval must be obtained, and all other eligibility criteria should be reviewed to ensure that the participant is otherwise eligible prior to performing the kidney biopsy; Kidney biopsy exception for anti-PLA2R antibody positive participants: Participants who are positive for anti-PLA2R antibodies at Screening and have not had a kidney biopsy performed within 5 years of signing the ICF may be eligible for the study without undergoing a kidney biopsy based on medical monitor review of screening tests confirming normal estimated glomerular filtration rate (eGFR), presence of nephrotic syndrome, hypoalbuminemia, positive anti-PLA2R antibody test (defined as an anti-PLA2R antibody titer ≥ 20 RU/mL), and documentation provided by the Investigator that the work-up for secondary causes of membranous nephropathy (MN) was negative with no identifiable secondary causes
  • Meets one of the following:; Newly diagnosed PMN, defined as having never received IST for PMN in the past; Relapsed PMN, defined as documented achievement of CR or partial remission (PR) after treatment with an IST for PMN followed by reappearance of nephrotic range proteinuria (urine protein to creatinine ratio [UPCR] ≥ 3.0 gram per gram [g/g] from a 24-hour urine collection or proteinuria ≥ 3.5 gram per 24 hour [g/24 h])
  • Participants must be on the maximally approved dose or maximally tolerated dose of at least one renin-angiotensin-aldosterone system (RAAS) inhibition therapy (e.g. angiotensin-converting enzyme inhibitor [ACEI], angiotensin receptor blocker [ARB], and/or mineralocorticoid receptor antagonists [MRA]) for at least 4 weeks prior to Screening. Participants not on the maximally approved dose of RAAS inhibition may be enrolled provided there is documented intolerance to maximal RAAS inhibition (e.g., angioedema, development of postural hypotension, lightheadedness, hyperkalemia, etc). Participants on MRA therapy alone at Screening must have documented prior intolerance of ACEI or ARB therapy. Participants who do not tolerate ACEI or ARB therapy are not required to start MRA therapy prior to Screening
  • A UPCR of ≥ 3.0 g/g (as determined by a 24-hour urine collection) or total proteinuria ≥ 3.5 g/24 h (as determined by a 24-hour urine collection) at Screening after best supportive care for at least 4 weeks prior to signing the ICF

Who cannot take part

  • Secondary cause of MN (e.g., malignancies, medications, systemic lupus erythematosus [SLE], hepatitis B, hepatitis C, etc)
  • Severe renal impairment is defined as an eGFR ≤ 30 mL/min/1.73m\^2 at Screening or including the need for dialysis or renal replacement therapy; Note: Other protocol-defined Inclusion/Exclusion criteria may apply

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Where in United States

Also in 10 other countries, 101 sites

  • University Hospitals Cleveland Medical Center*Cleveland, United StatesContact: Lazar, Andrew (principal investigator)Taking people
  • Nephrotex Research GroupDallas, United StatesContact: Sumit Kumar (principal investigator)Taking people
  • Henry Ford Hospital- A-Basement Research PharmacyDetroit, United StatesContact: Douglas Atchison (principal investigator)Taking people
  • The Nephrology Group, Inc. - FresnoFresno, United StatesContact: Yangming Cao (principal investigator)Taking people
  • ECU Physicians Nephrology and HypertensionGreenville, United StatesContact: Reginald Obi (principal investigator)Taking people
  • Apogee Clinical Research, LLCHuntsville, United StatesContact: Michael Quadrini (principal investigator)Taking people
  • Knoxville Kidney Center PLLCKnoxville, United StatesContact: George Newman (principal investigator)Taking people
  • University of Texas Medical BranchLeague City, United StatesContact: Shikha Wadhwani (principal investigator)Taking people
  • Academic Medical Research InstituteLos Angeles, United StatesContact: Mohamed El-Shahawy (principal investigator)Taking people
  • UCLA Health Connie Frank Kidney Transplant Center and General NephrologyLos Angeles, United StatesContact: Anjay Rastogi (principal investigator)Taking people
  • University of Wisconsin School of Medicine and Public HealthMadison, United StatesContact: Sarah Panzer (principal investigator)Taking people
  • Vanderbilt University Medical CenterNashville, United StatesContact: Neil Sanghani (principal investigator)Taking people
  • Elixia Health - Michigan Kidney Consultants, LLC - Elixia - PPDSPontiac, United StatesContact: US Biogen Clinical Trial CenterNo longer taking part
  • UCSF Medical CenterSan Francisco, United StatesContact: Christopher Carlos (principal investigator)Taking people
  • Stanford UniversityStanford, United StatesContact: Fahmeedah Kamal (principal investigator)Taking people
  • James J Peters Veterans Administration Medical Center - NAVREF - PPDSThe Bronx, United StatesContact: Chang Xu (principal investigator)Taking people

About the trial

What the trial wants to find out

In this study, researchers will learn more about the use of felzartamab in participants with primary membranous nephropathy, also known as PMN. In people with PMN, autoantibodies build up in the glomeruli of the kidney. Antibodies are proteins that help the body fight off infection. An autoantibody is a type of antibody that mistakenly targets and attacks the body's own tissues. Glomeruli are the filters of the kidney that remove waste and extra fluid from the body. In PMN, the build-up of autoantibodies in the glomeruli causes damage to the kidneys.

Read full original descriptionShow less

Kidney damage can lead to too much protein and blood leaking into the urine. High levels of protein in the urine, called proteinuria, are common in people with PMN. Symptoms of PMN can include swelling in the legs and body, tiredness, and high blood pressure. If left untreated, PMN can eventually lead to kidney failure.

In this study, researchers will learn more about how a study drug called felzartamab affects people with PMN. Felzartamab is a monoclonal antibody, which means it is an antibody made in a laboratory. Felzartamab can target immune cells that produce autoantibodies, helping to lower their buildup in the kidneys. The main goal of this study is to compare how felzartamab works compared to a drug called tacrolimus. Tacrolimus is another drug given to people with PMN and kidney disease.

The main question that researchers want to answer is:

* How many participants achieve a complete response after 104 weeks of treatment? * A complete response means that their urine protein levels decrease to a low level and their kidney function remains stable.

Researchers will also learn about:

* How long it takes before the participants' disease gets worse * How long the participants' urine protein levels stay low * How many participants develop antibodies against felzartamab in the blood? * How many participants achieve a complete response after 76 weeks of treatment * How many participants have medical problems during the study * How felzartamab is processed by the body * How felzartamab affects participants' tiredness and overall physical health

The study will be done as follows:

* Participants will be screened to check if they can join the study. This may take up to 42 days. * Participants will be randomized to receive either felzartamab as intravenous (IV) infusions or tacrolimus, taken orally as tablets. * If participants have worsening kidney function or worsening proteinuria, or if their PMN relapses, or if they show no signs of improvement in their PMN, they will have a chance to receive rescue treatment. * If a participant stops treatment early, there will be follow-up visits every 12 weeks until they reach Week 104. * In total, participants will have up to 23 study visits. Participants who do not need rescue treatment will stay in the study for up to 104 weeks. Participants who need rescue treatment will stay in the study for up to 156 weeks.

The 2 groups in the trial

  • Open-Label Treatment PhaseTreatment being tested

    Participants will receive several intravenous (IV) doses of felzartamab or oral tacrolimus in the Open-Label Treatment Phase.

    Treatment: Felzartamab and Tacrolimus

  • Non-Responder Treatment PhaseTreatment being tested

    Participants initially randomized to felzartamab or tacrolimus who meet rescue criteria may receive regional standard of care immunosuppressive therapy (IST) per Investigator discretion or several IV doses of felzartamab, respectively, in the Non-Responder Treatment Phase.

    Treatment: Felzartamab and Standard of Care IST

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
An Open-Label, Multicenter, Randomized Phase 3 Study Evaluating the Efficacy and Safety of Felzartamab in Participants With Primary Membranous Nephropathy (PMN) [PROMINENT]
Fit questions
Built from NCT06962800, who can take part
Record updated
9 November 2026